drugset / Trial / NCT06093542

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD7503 in Japanese Healthy Participants.

NCT06093542 ↗

Phase 1 Completed 12 enrolled AstraZeneca
RandomizedParallel-groupSingle-blindTreatment

Summary

The study will evaluate the safety, tolerability, and the pharmacokinetics (PK) of AZD7503 following multiple subcutaneous doses in healthy Japanese participants.

Timeline

Start
2023-10-25
Primary completion
2024-03-20
Completion
2024-03-20

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD7503 Unknown — Subcutaneous

Indications

No indication recorded.